

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/658,890	09/09/2003		Robert J. McKinnon	3170-19	3206
22442	7590	09/29/2005		EXAM	INER
SHERIDA 1560 BROA		PC	SZMAL, BRIAN SCOTT		
SUITE 1200				ART UNIT PAPER NUMBER	
DENVER,	CO 8020	2	3736		
				DATE MAILED: 00/20/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
Office Action Commons	10/658,890	MCKINNON ET AL.			
Office Action Summary	Examiner	Art Unit			
	Brian Szmal	3736			
The MAILING DATE of this communication appe Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period with Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	TE OF THIS COMMUNICATION 6(a). In no event, however, may a reply be tim ill apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONED	l. ely filed the mailing date of this communication. 0 (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on	٠.				
2a) ☐ This action is FINAL . 2b) ☑ This	<u> </u>				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4) ☐ Claim(s) 1-18 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1,2,4,7,8,10,13,15 and 16 is/are reject 7) ☐ Claim(s) 3,5,6,9,11,12,14,17 and 18 is/are obje 8) ☐ Claim(s) are subject to restriction and/or	ed. cted to.				
Application Papers					
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) acce Applicant may not request that any objection to the decouple of the correction of the decouple of the correction of the original of the	epted or b) objected to by the E Irawing(s) be held in abeyance. See on is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list of 	have been received. have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No d in this National Stage			
Attachment(s)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 9-9-03.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:				

Specification

1. The abstract of the disclosure is objected to because the abstract exceeds 150 words. Correction is required. See MPEP § 608.01(b).

Claim Objections

- Claim 17 is objected to because of the following informalities: In line 2,
 "plunger." should read as "plunger". Appropriate correction is required.
- 3. Claim 18 is objected to because of the following informalities: The claim is objected to due to the claim not providing a further limitation for the method of sterilizing the syringes. The claim appears that it should depend upon Claim 10 instead of Claim 15. Appropriate correction is required.

Claim Rejections - 35 USC § 102

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 5. Claims 1, 2, 4, 7 and 8 are rejected under 35 U.S.C. 102(b) as being anticipated by Caselgrandi et al (4,542,749).

Caselgrandi et al disclose a syringe for use in a biopsy and further disclose a syringe body that includes an outer member (2) having a distal end and a proximal end and an inner member having a distal end and a proximal end; a bridge (4) integrally formed with

the inner (3) and outer members (2) and disposed between the proximal and distal ends thereof that joins the inner (3) and outer members (2) together; a vent (22) that allows air to escape and being joined to at least one of the inner (3) and outer members (2); the bridge (4) is more adjacent to the distal ends than the proximal ends; the syringe is a first syringe and further including a second syringe joined to the first syringe for at least one of: creating negative pressure to draw blood into the first syringe and providing positive pressure to cause blood to move from the first syringe; the bridge (4) is spaced from the distal ends of the inner (3) and outer members (2); and the proximal end of the inner member (3) is substantially coterminous with the proximal end of the outer member (2). See Figures 2 and 5.

Page 3

6. Claims 10 and 13 are rejected under 35 U.S.C. 102(b) as being anticipated by Motta (5,032,117).

Motta discloses a tandem syringe and further discloses providing a first syringe; coupling a second syringe to the first syringe; controlling blood flow relative to the first syringe using the second syringe; and causing blood to flow from the first syringe in order to test the blood. See Figures 2 and 3.

7. Claims 15 and 16 are rejected under 35 U.S.C. 102(b) as being anticipated by Goodsir et al (4,753,345).

Goodsir et al discloses a hypodermic syringe tray and further disclose providing a plurality of syringes including at least a first and second syringes in a container, the first and second syringes being adjacent to each other and being free of any package that separates the first and second syringes from each other; sterilizing the plurality of

Application/Control Number: 10/658,890 Page 4

Art Unit: 3736

syringes in the container; and each of the first and second syringes has a distal end adjacent to which a distal cap is joined before the sterilization. See Column 1, lines 37-47; Column 2, lines 6-34; and Figure 1.

Allowable Subject Matter

8. Claims 3, 5, 6, 9, 11, 12 and 14 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian Szmal whose telephone number is (571) 272-4733. The examiner can normally be reached on Monday-Friday, with second Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Max Hindenburg can be reached on (571) 272-4726. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/658,890 Page 5

Art Unit: 3736

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

BS

MAX F. HINDENBURE
SUPERVISORY PATENT EXAMINER
COMNOLOGY CENTER 3700